Quibim’s AI-based Early-stage Neurological Disease Quantification Software for Quantification of Early Brain Atrophy and Lesions Authorized for Use in US, EU and UK
Summary
December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based software to identify early-stage neurodegenerative diseases, is pleased to announce today the launch of QP-Brain. With up to one billion individuals affected by neurological diseases worldwide, plus global increases in the number of people reaching an older age when neuro-diseases are more common, the demand for quantitative assessments to detect early-stage changes in the brain has never been higher. In order to resolve the issue, healthcare institutions require advanced and versatile quantitative AI-based tools that can also provide secure transfer and storage of patients’ data and augment the workflow of clinicians. QP-Brainwas therefore designed by Quibim to facilitate quantitative analysis of patients’ brains by using an AI-based tool that automatically quantifies and displays results based on the data from MRI Scans directly in PACS. At Quibim our mission is to develop AI technology that augments the essential role played by human medical experts to improve patient outcomes, by detecting neurological diseases and cancers much earlier than is currently possible.”